PATTERNS OF OTC USE IN THE NETHERLANDS

2 May 1993

Although the non-prescription market in the Netherlands has been difficult to monitor in the past due to the large number of non-registered products, a new report from Neprofarm, the newly-formed Dutch nonprescription drug manufacturers association, has provided some up-to-date data on the sector.

In 1992, the total over-the-counter pharmaceutical market in Holland was worth 377.7 million guilders (around $210 million), a rise of 6.4% over the 1991 level. Neprofarm believes there is still a great deal of growth potential in a country where, according to surveys, over 70% of people are unwilling to use OTC medication. The following table breaks down the OTC sales by category.

OTC Category Market Growth List V Drugs 167.7 4.8% Pharmacy-only medicines 71.9 4.2% Unregistered drugs 138.1 9.6% Total Market 377.7 6.4%

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight